Assenagon Asset Management S.A. Has $4.31 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Assenagon Asset Management S.A. reduced its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 13.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,588 shares of the specialty pharmaceutical company’s stock after selling 23,126 shares during the quarter. Assenagon Asset Management S.A. owned 0.47% of Collegium Pharmaceutical worth $4,314,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Victory Capital Management Inc. boosted its holdings in Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after purchasing an additional 215,874 shares during the last quarter. Emerald Advisers LLC boosted its holdings in Collegium Pharmaceutical by 27.2% during the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after purchasing an additional 177,129 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after purchasing an additional 175,892 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its holdings in Collegium Pharmaceutical by 24.9% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company’s stock worth $25,591,000 after purchasing an additional 131,835 shares during the last quarter. Finally, Empowered Funds LLC purchased a new position in Collegium Pharmaceutical during the third quarter worth about $4,693,000.

Insiders Place Their Bets

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $33.35 on Tuesday. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of 14.38 and a beta of 0.82. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52 week low of $28.39 and a 52 week high of $42.29. The firm’s 50-day simple moving average is $30.57 and its two-hundred day simple moving average is $34.12.

Wall Street Analyst Weigh In

Several research firms recently weighed in on COLL. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday, January 10th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.80.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.